The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...

Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD) with inadequate response to at least 2 oral antidepressants.

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Spravato is the first and only approved monotherapy for adults with refractory major depressive disorder. Approval of ...